{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:59:33Z","timestamp":1783645173774,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.lungcan.2004.06.003","type":"journal-article","created":{"date-parts":[[2004,7,24]],"date-time":"2004-07-24T10:25:55Z","timestamp":1090664755000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines"],"prefix":"10.1016","volume":"47","author":[{"given":"Seiji","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Segawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Nogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taira","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2004.06.003_BIB1","first-page":"228","article-title":"Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents","volume":"7","author":"Argiris","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1586\/14737140.1.2.211","article-title":"Advances in systemic therapy of small cell cancer of the lung","volume":"1","author":"Daniels","year":"2001","journal-title":"Expert Rev. Anticancer Ther"},{"issue":"Suppl. 6","key":"10.1016\/j.lungcan.2004.06.003_BIB3","first-page":"23","article-title":"Cisplatin\/etoposide versus carboplatin\/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials","volume":"21","author":"Kosmidis","year":"1994","journal-title":"Semin. Oncol"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0169-5002(99)00050-1","article-title":"Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. \u2018Petites Cellules\u2019 Group","volume":"25","author":"Urban","year":"1999","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB5","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM199211123272006","article-title":"Chemotherapy of lung cancer","volume":"327","author":"Ihde","year":"1992","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB6","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0093-7754(01)90259-3","article-title":"Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies","volume":"28","author":"Green","year":"2001","journal-title":"Semin. Oncol"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB8","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB9","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB10","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2401770","article-title":"Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines","volume":"14","author":"Tassone","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0301-472X(01)00618-X","article-title":"Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma","volume":"29","author":"Cruz","year":"2001","journal-title":"Exp. Hematol"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB13","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood-2003-01-0305","article-title":"The third-generation bisphosphonate Zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate","volume":"102","author":"Kuroda","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1023\/A:1022621622063","article-title":"A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice","volume":"20","author":"Zhang","year":"2003","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF02983531","article-title":"Anti-proliferative efficacy of the third generation bisphosphonate zoledronic acid combined with other anti-cancer drugs in leukemic cell lines","volume":"79","author":"Kimura","year":"2004","journal-title":"Int. J. Hematol"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0026-895X(24)12827-1","article-title":"Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation","volume":"59","author":"Reszka","year":"2001","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB17","first-page":"2416","article-title":"Preferential expression of c-kit protooncogene transcripts in small cell lung cancer","volume":"51","author":"Sekido","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/bjc.1993.7","article-title":"Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor\/scatter factor and stem cell factor, in SCLC cell lines and xenografts","volume":"67","author":"Rygaard","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB19","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1038\/sj.onc.1203698","article-title":"Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571","volume":"19","author":"Wang","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB20","first-page":"3319","article-title":"The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth","volume":"6","author":"Krystal","year":"2000","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB21","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1200\/JCO.2002.20.24.4618","article-title":"The guard dies, it does not surrender! progress in the management of small-cell lung cancer?","volume":"20","author":"Johnson","year":"2002","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB22","first-page":"1395","article-title":"Limited small-cell lung cancer: a potentially curable disease discussion","volume":"14","author":"Sherman","year":"2000","journal-title":"Oncology (Huntington)"},{"issue":"Suppl 6","key":"10.1016\/j.lungcan.2004.06.003_BIB23","first-page":"53","article-title":"New treatment agents for advanced small cell and non small cell lung cancer","volume":"22","author":"Bunn","year":"1995","journal-title":"Semin. Oncol"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J. Clin. Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.lungcan.2004.06.003_BIB25","first-page":"23","article-title":"Anti-tumor potential of bisphosphonates","volume":"95","author":"Green","year":"2000","journal-title":"Med. Klin"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB26","first-page":"4243","article-title":"Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion","volume":"55","author":"Sun","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB27","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors","volume":"272","author":"Whyte","year":"1997","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1006\/excr.2001.5440","article-title":"Inhibition of farnesyl protein transferase and MEK1, 2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras","volume":"273","author":"Brassard","year":"2002","journal-title":"Exp. Cell Res"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB29","doi-asserted-by":"crossref","first-page":"15309","DOI":"10.1074\/jbc.M201253200","article-title":"Inhibition of protein geranylgeranylation and RhoA\/RhoA kinase pathway induces apoptosis in human endothelial cells","volume":"277","author":"Li","year":"2002","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1749-6632.1999.tb07702.x","article-title":"MMP inhibition and downregulation by bisphosphonates","volume":"878","author":"Teronen","year":"1999","journal-title":"Ann. N. Y. Acad. Sci"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/348334a0","article-title":"Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death","volume":"348","author":"Hockenbery","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB32","first-page":"6","article-title":"Expression of bcl-2 in small cell lung carcinoma cells","volume":"54","author":"Ikegaki","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB33","first-page":"1036","article-title":"Small cell carcinomas of the lung express the Bcl-2 protein","volume":"145","author":"Ben-Ezra","year":"1994","journal-title":"Am. J. Pathol"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB34","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/1097-0142(19900901)66:5<868::AID-CNCR2820660510>3.0.CO;2-Z","article-title":"Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correction to clinical drug resistance","volume":"66","author":"Kuwazuru","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1365-2141.2003.04437.x","article-title":"How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics","volume":"122","author":"Salomo","year":"2003","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB36","unstructured":"Berenson J, Ravera C, Ma P, Deckert F, Sasaki Y, Saeki T, et al. Population pharmacokinetics of zometa [abstract]. Proc ASCO. 2000:209a."},{"key":"10.1016\/j.lungcan.2004.06.003_BIB37","first-page":"3551","article-title":"Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice","volume":"55","author":"Sasaki","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB38","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6600986","article-title":"Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro","volume":"88","author":"Tassone","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB39","first-page":"478","article-title":"Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience)","volume":"59","author":"Kraj","year":"2002","journal-title":"Acta Pol. Pharm"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J. Clin. Pharmacol"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1349-7006.2004.tb03202.x","article-title":"p53-independent anti-leukaemic effect of the third-generation bisphosphonate Zoledronate","volume":"95","author":"Kuroda","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB42","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0006-291X(02)00912-9","article-title":"A pro-apoptotic effect of the CDK inhibitor p57(Kip2) on staurosporine-induced apoptosis in HeLa cells","volume":"296","author":"Samuelsson","year":"2002","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB43","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB44","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB45","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.lungcan.2004.06.003_BIB46","unstructured":"FDA approves ZOMETA for treatment of cancer-related bone complications. Expert Rev Anticancer Ther 2 (2002) 137\u20138."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500204002600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500204002600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:15:09Z","timestamp":1759234509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500204002600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0169500204002600"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2004.06.003","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2004.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}